The historical rank and industry rank for PureTech Health's FCF Margin % or its related term are showing as below:
PRTCY'
s FCF Margin % Range Over the Past 10 Years
Min: -14143 Med: -1736.46 Max: -472.09
Current: -1827.24
During the past 13 years, the highest FCF Margin % of PureTech Health was -472.09%. The lowest was -14143.00%. And the median was -1736.46%.
PRTCY's FCF Margin % is ranked worse than 83.73% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs PRTCY: -1827.24
PureTech Health FCF Margin % Related Terms
PureTech Health FCF Margin % Historical Data
* Premium members only.
The historical data trend for PureTech Health's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRTCY vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, PureTech Health's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's FCF Margin % distribution charts can be found below:
* The bar in red indicates where PureTech Health's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health (PRTCY) has a FCF Margin % of -1,395.62% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PureTech Health and its competitors. According to the industry distribution chart, PureTech Health ranks #803 out of 959 companies in the Biotechnology industry, placing it in the top 83.7%.
Is PureTech Health's FCF Margin % too high?
PureTech Health's current FCF Margin % is -1,395.62%. Based on the distribution chart, PureTech Health ranks #803 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #803 out of 959 companies for FCF Margin %. This places PureTech Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PureTech Health and its competitors. PureTech Health's current FCF Margin % is -1,395.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current FCF Margin % is -1,395.62%. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For PureTech Health (PRTCY), the current FCF Margin % is -1,395.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (PRTCY) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for PRTCY:
FCF Margin %: -1,395.62%
GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score
Get the complete analysis for PRTCY
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRTCY has been successfully added to your 
